Algatechnologies Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Algatechnologies Ltd. - overview
Established
1998
Location
-, -, Israel
Primary Industry
Biotechnology
About
Algatechnologies Ltd. is a biotechnology company specializing in microalgae-derived products, focusing on health and wellness through natural ingredients. Founded in 1998 in Israel, Algatechnologies Ltd. produces high-quality microalgae products.
The company was acquired by Solabia S. A. S. in May 2019 from Grovepoint.
Doron Safrai and Udi Cottan serve as the CEO and Co-CEO, respectively. The firm has completed a total of 2 deals, with its most recent funding round being a Buyout of USD 15. 00 mn, raising a total of USD 15. 00 mn.
Algatech specializes in the production of high-quality microalgae-derived products, primarily focusing on AstaPure® Astaxanthin and BioGlena™ Beta Glucan. AstaPure® is a natural astaxanthin sourced from the microalgae Haematococcus pluvialis, renowned for its powerful antioxidant properties utilized in dietary supplements, cosmetics, and functional foods. BioGlena™, derived from the microalgae Euglena gracilis, is recognized for its immune-modulating properties, containing over 55% linear 1,3 beta-glucan, aimed at enhancing immune function across diverse demographics. The company serves a global client base spanning North America, Europe, and Asia, targeting sectors such as nutraceuticals, cosmetics, and animal nutrition.
Algatech generates revenue through the sale of its microalgae products, primarily engaging in B2B transactions with clients in the nutraceutical and cosmetic industries. The company utilizes a direct sales model involving partnerships with distributors and retailers to reach end consumers. Revenue structures include bulk sales agreements for AstaPure® and BioGlena™ products, priced to reflect their high purity and efficacy. The client base includes manufacturers of dietary supplements and cosmetics requiring sustainably sourced ingredients for product development.
Algatechnologies Ltd. is focused on expanding its product portfolio and market presence. Plans include launching new formulations aimed at health and wellness, leveraging recent funding to support R&D initiatives. The company is actively targeting expansion into Asian markets by 2023 to enhance its global footprint.
The recent Buyout funding of USD 15. 00 mn will be utilized to fuel these growth strategies.
Current Investors
TA Associates, Solabia Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.algatech.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Algatechnologies Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Algatechnologies Ltd. | - | ||||||||
| Buyout | Completed | Algatechnologies Ltd. | - |
Displaying 1 - 2 of 2
Algatechnologies Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.